Proteomic detection of cancer in asbestosis patients using SELDI-TOF discovered serum protein biomarkers.

Authors: Tooker, Brian C  Newman, Lee S  Bowler, Russell P  Karjalainen, Antti  Oksa, Panu  Vainio, Harri  Pukkala, Eero  Brandt-Rauf, Paul W 
Citation: Tooker BC, etal., Biomarkers. 2011 Mar;16(2):181-91. doi: 10.3109/1354750X.2010.543289. Epub 2011 Jan 14.
Pubmed: (View Article at PubMed) PMID:21231887
DOI: Full-text: DOI:10.3109/1354750X.2010.543289

OBJECTIVES: To identify biomarkers for cancer in asbestosis patients.
METHODS: SELDI-TOF and CART were used to identify serum biomarker profiles in 35 asbestosis patients who subsequently developed cancer and 35 did not develop cancer.
RESULTS: Three polypeptide peaks (5707.01, 6598.10, and 20,780.70 Da) could predict the development of cancer with 87% sensitivity and 70% specificity. The first two peaks were identified as KIF18A and KIF5A, respectively, and are part of the Kinesin Superfamily of proteins.
CONCLUSIONS: We identified two Kinesin proteins that can be potentially used as blood biomarkers to identify asbestosis patients at risk of developing lung cancer.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 12793066
Created: 2017-03-20
Species: All species
Last Modified: 2017-03-20
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.